We are driven to make a difference for patients and those who care for them.

At the heart of everything we do at Syros is our dedication to advancing medicines that provide a profound benefit for patients with difficult-to-treat diseases.

We are pioneering a new field of medicine focused on controlling the expression of genes. The genes expressed - turned on, off, up or down - in any given cell determine its type and function. When genes are expressed at the wrong time or in the wrong amounts, it changes the function of a cell, leading to disease. Because gene expression is fundamental to the function of all cells, we believe our pioneering approach has potential to create medicines that provide patients with a range of diseases the opportunity to live longer and enjoy a better quality of life.

We currently have three programs in clinical development: tamibarotene in defined subsets of patients with myelodysplastic syndrome and acute myeloid leukemia; SY-2101 in patients with acute promyelocytic leukemia; and SY-5609 in patients with pancreatic cancer and BRAF-mutant colorectal cancer. In addition, we have multiple programs in earlier stages of research for cancer, as well as genetic diseases, for which there is a dire need for better medicines.

We invite you to learn more about our programs and ongoing clinical trials, as well as to explore a select list of resources for these diseases.

Nancy Simonian, M.D.
Chief Executive Officer of Syros

Nancy Simonian, M.D.
Chief Executive Officer of Syros